Phase I/II Study of Combination Veltuzumab (Anti-CD20) and Fractionated 90Y- Epratuzumab (Anti-CD22) Radioimmunotherapy in Patients With Follicular Lymphoma
Phase of Trial: Phase I/II
Latest Information Update: 05 Jun 2017
At a glance
- Drugs Epratuzumab Y-90 (Primary) ; Veltuzumab (Primary)
- Indications Follicular lymphoma
- Focus Adverse reactions; Therapeutic Use
- 27 Apr 2017 Status changed from active, no longer recruiting to discontinued due to slow patient accrual.
- 07 Feb 2017 Planned End Date changed from 1 Jun 2013 to 31 Dec 2017.
- 07 Feb 2017 Status changed from recruiting to active, no longer recruiting.